Reports Q4 revenue $19.4M vs $17.5M last year. “We are proud to close out 2024 with another record-breaking quarter, marking our fourteenth ...

Iradimed Corporation (NASDAQ:IRMD – Get Free Report) shares gapped down prior to trading on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

IV treatment is one of the most traditionalist ... Not surprising that medical devices such as infusion pumps, infusion monitors, or drip counters today are not only perceived as a tool for ...

Baxter might have faced fourth-quarter hurdles from Hurricane Helene. However, it expects growth in infusion therapies, ...

On January 22, 2025, the Lions Club of Penetanguishene presented a cheque for $5,200 to Victoria Evans, community Giving ...

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients ...

IRadimed Corporation achieves record Q4 2024 revenue, driven by IV pump demand and monitor sales focus. Learn about their growth strategy & 2025 outlook.

The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...